EP1478329B1 - Orally administrable composition for the photoprotection of the skin - Google Patents
Orally administrable composition for the photoprotection of the skin Download PDFInfo
- Publication number
- EP1478329B1 EP1478329B1 EP03742550A EP03742550A EP1478329B1 EP 1478329 B1 EP1478329 B1 EP 1478329B1 EP 03742550 A EP03742550 A EP 03742550A EP 03742550 A EP03742550 A EP 03742550A EP 1478329 B1 EP1478329 B1 EP 1478329B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bifidobacterium
- lactic acid
- cncm
- acid bacterium
- lactobacillus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
Definitions
- the present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical composiitons, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and its use to improve the photoprotection of the skin.
- the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, and a yeast extract included into an orally acceptable carrier.
- the present invention further relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
- solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
- the invention relates to oral administration to the individual of a composition
- a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier and its use for improving the photoprotective function of the skin.
- the combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.
- NCC designates Nestlé Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland).
- photoprotection is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.
- the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative.
- Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastrointestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic microorganisms have been found, which all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.
- composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.
- the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifdobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, or a mixture thereof.
- Lactobacilli and/or Bifidobacteria are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus para
- strains Lactobacillus johnsonii NCC 533, Lactobacillus paracasei NCC 2461, Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Dondel Roux, F-75024 Paris cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.
- the strain of Bifidobacterium lactis (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.
- the probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder.
- culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form.
- the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s) /metabolite (s).
- Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.
- the probiotic lactic acid bacteria may be present in the carrier in an amount of at least 10 5 cfu/g of carrier and preferably from 10 5 to 10 15 cfu/g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/g of orally acceptable carrier.
- the carotenoid may be a carotenoid with or without provitamin A activity. It may be ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
- the carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art.
- the carotenoid may be present in the carrier in an amount of from 10 -12 % to 20% by weight and preferably from 0,00001 mg to 50 mg/day and more preferably from 0.001 mg to 30mg/day.
- a mixture of a plurality of lactic acid bacteria or carotenoids may also be used.
- the carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic microorganism and the carotenoid may be included.
- food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding.
- the nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.
- the composition according to the invention may further comprise bioactive molecules or yeast extracts, for example.
- the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina .
- the yeast may be selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhodutorula, and more preferably Saccharomyces caerevisae (baker's yeast).
- Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 10 5 cfu/ g of orally acceptable carrier, preferably from about 10 5 to 10 15 cfu/ g of orally acceptable carrier, and more preferably from 10 7 to 10 12 cfu/ g of orally acceptable carrier, said amount depending on the nature and activity of the particular yeast.
- composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.
- composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.
- the invention relates to oral administration to an individual a composition
- the amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 10 5 to 10 15 organisms, which organism may be alive or dead, and from 0,00001 mg to 50 mg of carotenoids, would usually are adequate.
- composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun.
- ultraviolet radiation in particular exposure to sun.
- ⁇ -carotene is provided by Roche
- Lycopene is provided by Lycored
- Lyophilized S.cerevissae is provided by BioSpringer
- Latobacillus CNCM I-1225 dry mix Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 dry mix are prepared so that they contain 1.10 8 to 1.10 9 organisms.
- a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
- composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Zeaxanthine 10 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
- composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Bifidobacterium CNCM I-2168 dry mix 30 mg Latobacillus CNCM I-1225 dry mix 30 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- a photoprotective daily orally administrable composition is prepared as follows: Lycopene 2.5 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-2116 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
- composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lycopene 2.5 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
- composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- a photoprotective daily orally administrable composition is prepared as follows: ⁇ -carotene 4.7 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg
- composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to orally administrable composition or pharmaceutical compositions, or cosmetical composiitons, for the protection of the skin against negative effects from the environment, in particular exposure to solar radiation, which is orally administrable, and its use to improve the photoprotection of the skin.
- The continuous decrease of the atmosphere's ozone layer with the concurrent increase of ultraviolet radiation reaching the planet's surface has attracted a great deal of interest in its potential consequence on human health. Although exposure to ultraviolet radiation is needed for humans to produce vitamin D, growing evidence suggests that extensive exposure to sun-light, in particular to ultraviolet radiation, causes a variety of problems in the skin, including induction of certain skin cancers and induction of accelerated skin ageing.
- In addition to these established health concerns, research has also provided evidence suggesting that exposure to ultraviolet radiation may negatively affect a variety of immune responses in living beings both locally, within the UV-irradiated skin, and also systemically, i.e. at sites distant from the irradiated skin.
- It is thus important to alleviate the detrimental effects of ultraviolet radiation on the skin, and also prevent the development of erythema, oedema and/or flaking or scaling (hyperkeratosis) of the skin.
- In the art, there have been several attempts, such as by using sunscreens or other particular pharmacological agents.
- In J. Invest. Dermatol., 97 (1991), 624-628 it is reported that topical application of ultraviolet radiation-absorbing compounds (sunscreens) is effective in preventing ultraviolet radiation-induced erythema and edema but cannot prevent UV-light induced immuno-suppression. This finding was confirmed by several other studies, according to which sunscreens seems to prevent inflammation or irritation but do not provide complete prophylactic protection against the immuno-suppressive effects of ultraviolet radiation.
- On the other hand, In FR 2698 268 (L'Oreal) an orally administrable composition comprising a combination of at least one amino-acid, salt of copper and a mix of vitamins has been shown to protect the skin against ultraviolet radiation.
- However, there is still a need in the art for an orally administrable composition, which is capable to improve and/or reinforce the photoprotective function of the skin.
- Accordingly, in a first aspect the present invention aims to provide an orally administrable composition for the photoprotection of the skin which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, and a yeast extract included into an orally acceptable carrier.
- The present invention further relates to the use of a photoprotecting effective amount of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier for preparing an orally administrable composition for protecting the skin against solar radiations such as ultraviolet and all related skin disorders, such as erythema, inflammation, sun burn, barrier function, photoageing, alteration of the immune system, for example.
- In a last aspect, the invention relates to oral administration to the individual of a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier and its use for improving the photoprotective function of the skin.
- The combination according to the present invention has a particular beneficial effect on skin protection and coloration of the skin that helps to reduce the effects of solar radiation-related stress on skin.
- Within the following description, "NCC" designates Nestlé Culture Collection (Nestlé Research Center, Vers-chez-les-Blanc, Lausanne, Switzerland). The term "photoprotection" is used to describe attempt to block or reduce the adverse clinical, histological and immunological effects of solar radiation exposure on the skin.
- According to the present invention, the subject compositions comprise, as the active agents therefor, combinatory immixture of at least one probiotic lactic acid bacterium or a culture supernatant thereof, and at least one carotenoid or derivative.
- Indeed, it has now surprisingly and unexpectedly been determined that admixture of these two very specific constituents elicits an enhanced effect or response in respect of the photoprotection of the skin.
- Probiotics are non-pathogenic and non-toxigenic organisms that survive passage through the stomach and small intestine. Upon continuous ingestion by the host they eventually may colonize the gut to a substantial extent thus competing with other potentially pathogenic bacteria for nutrients and/or attachment sites on the gastrointestinal wall and reducing their numbers and reducing or preventing infections. Until now a number of different probiotic microorganisms have been found, which all are reported to exert their effect in the gut via the production of toxins, metabolic by-products, short chain fatty acids and the like.
- It has now been shown that probiotics do also exert an effect in an individual's body at a location distant from the region in which they colonize it. And particularly, it has been surprisingly found that a composition having a synergistic photoprotective effect on the skin may be obtained by combining into an orally acceptable carrier, a probiotic microorganism and an active compound such as carotenoid.
- In a preferred embodiment, the probiotic to be included into the carrier is selected from the group consisting of lactic acid bacteria, in particular Lactobacilli and/or Bifidobacteria and are more preferably Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifdobacterium breve, Bifidobacterium longum, Bifidobacterium animalis, Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, or a mixture thereof.
- According to a most preferred embodiment the strains Lactobacillus johnsonii NCC 533, Lactobacillus paracasei NCC 2461, Bifidobacterium adolescentis NCC 251 and Bifidobacterium longum NCC 490 were deposited by way of an example, under the Budapest Treaty with the Institut Pasteur (28 rue du Docteur Roux, F-75024 Paris cédex 15) on 30.06.92, 12.01.99, 15.04.99 and 15.03.99, respectively and under the deposit number CNCM I-1225, CNCM I-2116, CNCM I-2168 and CNCM I-2170, respectively.
- The strain of Bifidobacterium lactis (ATCC27536) provided by Hansen (Chr. Hansen A/S, 10-12 Boege Alle, P.O. Box 407, DK-2970 Hoersholm, Danemark) can also be used.
- The probiotic microorganism according to the present invention may be included in a live form, dead form, semi-active or in deactivated form and fragments or fractions originating from the microorganism either live or dead e.g. as a lyophilized powder. Also culture supernatants of the microorganisms may be included in the products, optionally in concentrated form. It may also be included in an encapsulated form. When using a supernatant of a probiotic's culture the supernatant may be used as such or may be subjected to one or more purification steps prior to inclusion into the product, so as to concentrate or isolate the active ingredient (s) /metabolite (s). Method and techniques for purifying compounds and detecting the activity thereof in the fractions obtained are well known to the skilled person.
- The probiotic lactic acid bacteria may be present in the carrier in an amount of at least 105 cfu/g of carrier and preferably from 105 to 1015 cfu/g of orally acceptable carrier, and more preferably from 107 to 1012 cfu/g of orally acceptable carrier.
- The carotenoid may be a carotenoid with or without provitamin A activity. It may be β-carotene, γ-carotene, α-carotene, lycopene, zeaxanthine and luteine, or a mixture thereof. The carotenoid may be from synthetic or natural origin or contained in a natural extract. When the carotenoid is from natural origin, it is preferably obtained from plant material, in which the plant is grown in-vivo or in-vitro. Method for extracting the carotenoids is well known in the art. The carotenoid may be present in the carrier in an amount of from 10-12% to 20% by weight and preferably from 0,00001 mg to 50 mg/day and more preferably from 0.001 mg to 30mg/day.
- A mixture of a plurality of lactic acid bacteria or carotenoids may also be used.
- The carrier may be any food or pharmaceutical product, or a nutritional supplement for oral administration or a composition for oral administration, wherein the probiotic microorganism and the carotenoid may be included. Examples for food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding. The nutritionally supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.
- The composition according to the invention may further comprise bioactive molecules or yeast extracts, for example. In a preferred embodiment, the yeast is any food-grade yeast selected from the group consisting of Ascomycotina or Deuteromycotina . In a preferred embodiment, the yeast may be selected from the group consisting of Debaryomyces, Kluyveromyces, Saccharomyces, Yarrowia, Zygosaccharomyces, Candida and Rhodutorula, and more preferably Saccharomyces caerevisae (baker's yeast).
- Such yeast may be used in the form of dried or lyophilized extracts. It may be present in the carrier in an amount of at least 105 cfu/ g of orally acceptable carrier, preferably from about 105 to 1015 cfu/ g of orally acceptable carrier, and more preferably from 107 to 1012cfu/ g of orally acceptable carrier, said amount depending on the nature and activity of the particular yeast.
- The composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives.
- The composition according to the invention provides a surprising and synergistic protective and preventive effect of the skin.
- Accordingly, in another aspect, the invention relates to oral administration to an individual a composition comprising a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid or derivative, in an orally acceptable carrier. and its use for improving the photoprotective function of the skin.
- The amount of the composition to be consumed by the individual will depend on the desirable effect. However, an amount of the composition to provide a daily amount of about 105 to 1015 organisms, which organism may be alive or dead, and from 0,00001 mg to 50 mg of carotenoids, would usually are adequate.
- The composition is administered to an individual before or during the exposure to ultraviolet radiation, in particular exposure to sun. When the exposure period is foreseeable, it is desirable to start the consumption before the exposure and preferably 1 to 2 months before, and to prolong consumption during exposure.
- The following examples are given by way of illustration. All percentages are given by weight unless otherwise indicated.
- In the following examples 1 to 6, β-carotene is provided by Roche, Lycopene is provided by Lycored, Lyophilized S.cerevissae is provided by BioSpringer, Latobacillus CNCM I-1225 dry mix, Lactobacillus CNCM I-2116 or Bifidobacterium CNCM I-2168 dry mix are prepared so that they contain 1.108 to 1.109 organisms.
- A photoprotective daily orally administrable composition is prepared as follows:
β-carotene 4.7 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg - The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- A photoprotective daily orally administrable composition is prepared as follows:
β-carotene 4.7 mg Zeaxanthine 10 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg - The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- A photoprotective daily orally administrable composition is prepared as follows:
β-carotene 4.7 mg Lycopene 2.5 mg Bifidobacterium CNCM I-2168 dry mix 30 mg Latobacillus CNCM I-1225 dry mix 30 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg - A photoprotective daily orally administrable composition is prepared as follows:
Lycopene 2.5 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-2116 dry mix 50 mg - The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- A photoprotective daily orally administrable composition is prepared as follows:
β-carotene 4.7 mg Lycopene 2.5 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg - The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
- A photoprotective daily orally administrable composition is prepared as follows:
β-carotene 4.7 mg Lyophilized S.cerevissae 75 mg Latobacillus CNCM I-1225 dry mix 50 mg Glucidex IT 19 (maltodextrin powder) QSP 500 mg - The composition is administered to the individual in an amount of 2x500 mg daily, which provides a protective and preventive effect of the skin.
Claims (14)
- An orally administrable composition for the photoprotection of the skin which comprises i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one carotenoid included into an orally acceptable carrier, said composition further comprises a yeast extract.
- A composition according to claim 1, in which the lactic acid bacterium is selected from the group consisting of Lactic acid bacteria, preferably Lactobacilli and/ or Bifidobacteria.
- A composition according to claim 1 or 2, in which the lactic acid bacterium is Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidabacerium animalis, , Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, or a mixture thereof.
- A composition according to one of claims 1 to 3, in which the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168 or CNCM I-2170.
- A composition according to one of claims 1 to 4, in which the probiotic lactic acid bacterium is included into the carrier in a live form, semi-active or in deactivated form, preferably as a lyophilized powder attention.
- A composition according to one of claims 1 to 5, wherein the carotenoid is a carotenoid with or without provitamin A activity, such as β-carotene, γ-carotene, α-carotene, lycopene, zeaxanthine and luteine, or a mixture thereof.
- A composition according to one of claims 1 to 6, wherein the carrier is a food or a pharmaceutical product, or a nutritional supplement for oral administration.
- A composition according to claim 6, wherein the food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding.
- A composition according to claim 7, wherein the nutritional supplement for oral administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions.
- Use of at least one probiotic lactic acid bacterium or a culture supernatant thereof and at least one carotenoid, included into an orally acceptable carrier, for preparing an orally administrable composition for the protection of the skin against solar radiations and attenuating or preventing all related skin disorders.
- The use according to claim 10, in which the lactic acid bacterium is Lactobacillus johnsonii, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus casei or Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacerium animalis, , Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, or a mixture thereof
- The use acording to claim 10 or 11, wherein the lactic acid bacterium is CNCM I-1225, CNCM I-2116, CNCM I-2168, CNCM I-2170 or ATCC 27536.
- The use according to one of claims 10 to 12, wherein the probiotic lactic acid bacterium is present in the carrier in an amount of from 105 to 1012 cfu/g carrier.
- The use according to one of claims 10 to 12, wherein the carotenoid is present in the carrier in an amount of from 10-12% to 20% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03742550A EP1478329B1 (en) | 2002-02-21 | 2003-02-18 | Orally administrable composition for the photoprotection of the skin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02075703 | 2002-02-21 | ||
EP02075703 | 2002-02-21 | ||
PCT/EP2003/001685 WO2003070203A1 (en) | 2002-02-21 | 2003-02-18 | Orally administrable composition for the photoprotection of the skin |
EP03742550A EP1478329B1 (en) | 2002-02-21 | 2003-02-18 | Orally administrable composition for the photoprotection of the skin |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1478329A1 EP1478329A1 (en) | 2004-11-24 |
EP1478329B1 true EP1478329B1 (en) | 2006-05-10 |
Family
ID=27741186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03742550A Expired - Lifetime EP1478329B1 (en) | 2002-02-21 | 2003-02-18 | Orally administrable composition for the photoprotection of the skin |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050069505A1 (en) |
EP (1) | EP1478329B1 (en) |
JP (1) | JP2005526038A (en) |
KR (1) | KR20040096604A (en) |
CN (1) | CN1301708C (en) |
AR (1) | AR038594A1 (en) |
AT (1) | ATE325604T1 (en) |
AU (1) | AU2003232184B2 (en) |
BR (1) | BR0307875B1 (en) |
CA (1) | CA2477144C (en) |
DE (1) | DE60305159T2 (en) |
DK (1) | DK1478329T3 (en) |
ES (1) | ES2263990T3 (en) |
HK (1) | HK1079104A1 (en) |
MX (1) | MXPA04008177A (en) |
NO (1) | NO20043848L (en) |
PL (1) | PL372146A1 (en) |
PT (1) | PT1478329E (en) |
RU (1) | RU2309760C2 (en) |
TW (1) | TWI344845B (en) |
UA (1) | UA77066C2 (en) |
WO (1) | WO2003070203A1 (en) |
ZA (1) | ZA200407551B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1490077E (en) * | 2002-02-21 | 2008-02-28 | Oreal | A photoprotective orally administrable composition for skin |
DE60305159T2 (en) * | 2002-02-21 | 2007-03-15 | Société des Produits Nestlé S.A. | ORAL ADMINISTRATIVE COMPOSITION FOR THE PROTECTION OF THE SKIN FROM LIGHT |
US8088363B2 (en) * | 2002-10-28 | 2012-01-03 | Zeavision Llc | Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
GB2399752A (en) * | 2003-03-26 | 2004-09-29 | Micap Plc | Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant |
EP1706126A4 (en) * | 2003-12-04 | 2009-07-01 | Biofilms Strategies Inc | Methods and compositions for preventing biofilm formations, reducing existing biofilms, and for reducing existing biofilms, and for reducing populations of bacteria |
WO2006037922A1 (en) * | 2004-10-04 | 2006-04-13 | L'oreal | Cosmetic and/or dermatological composition for sensitive skins |
FR2876029B1 (en) * | 2004-10-04 | 2008-11-14 | Oreal | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKINS. |
US20060269508A1 (en) | 2005-03-29 | 2006-11-30 | Trejo Amy V | Means for regulating the cosmetic appearance and/or health of human keratinous tissue |
EP1865795A1 (en) | 2005-04-08 | 2007-12-19 | Alimentary Health Limited | Methods of use of orally administered probiotic bifidobacteria for human beauty benefits |
AT501919B1 (en) * | 2005-06-14 | 2008-09-15 | Erber Ag | PROBIOTIC, HEALTH OR BZW. PERFORMANCE-ADDING FEED AND / OR DRINKING WATER SUPPLEMENT FOR ANIMALS AND ITS USE |
US20110082218A1 (en) * | 2006-06-15 | 2011-04-07 | Karin Wertz | Treatment and modulation of gene expression and skin aging |
FR2920304B1 (en) | 2007-09-04 | 2010-06-25 | Oreal | COSMETIC USE OF LYSAT BIFIDOBACTERIUM SPECIES FOR THE TREATMENT OF DROUGHT. |
FR2920305B1 (en) | 2007-09-04 | 2010-07-30 | Oreal | USE OF A SPECIFIC BIFIDOBACTERIUM LYSATE FOR THE TREATMENT OF SENSITIVE SKINS. |
US20090118229A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
US20090118227A1 (en) | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
US20090118228A1 (en) * | 2007-11-07 | 2009-05-07 | Bristol-Myers Squibb Company | Carotenoid-containing compositions and methods |
FR2942719B1 (en) | 2009-03-04 | 2011-08-19 | Oreal | USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION |
EP2429538B1 (en) * | 2009-05-11 | 2015-10-21 | Nestec S.A. | Non-replicating bifidobacterium longum ncc2705 and immune disorders |
FR2953408B1 (en) * | 2009-12-08 | 2013-02-08 | Oreal | ACTIVE PROBIOTIC MICROORGANISMS FOR SKIN DYE SKIN |
WO2011083738A1 (en) * | 2010-01-06 | 2011-07-14 | 株式会社ヤクルト本社 | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application |
WO2012002322A1 (en) * | 2010-06-28 | 2012-01-05 | 株式会社ヤクルト本社 | Skin properties improving agent for oral administration |
US9259019B2 (en) * | 2010-11-11 | 2016-02-16 | Mars, Incorporated | Bifidobacteriumstrain |
AR085943A1 (en) | 2011-04-08 | 2013-11-06 | Chr Hansen As | ANTIMICROBIAL COMPOSITION |
JP2014516589A (en) | 2011-06-20 | 2014-07-17 | エイチ.ジェイ.ハインツ カンパニー | Probiotic Composition and Method (PROBIOTICCOMPOSITIONANDMETHODS) |
US9113653B2 (en) * | 2011-08-19 | 2015-08-25 | Steven J Maranz | Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition |
US9173910B2 (en) | 2012-02-29 | 2015-11-03 | The General Hospital Corporation | Compositions of microbiota and methods related thereto |
MX351627B (en) | 2012-04-09 | 2017-10-23 | Chr Hansen As | Bioprotection using lactobacillus paracasei strains. |
PL2836587T3 (en) | 2012-04-09 | 2017-08-31 | Chr. Hansen A/S | Bioprotection using lactobacillus rhamnosus strains |
CA2964480A1 (en) | 2014-10-31 | 2016-05-06 | Whole Biome Inc. | Methods and compositions relating to microbial treatment and diagnosis of disorders |
SG11201707657UA (en) * | 2015-03-18 | 2017-10-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of skin disorders |
KR20180056775A (en) | 2015-10-07 | 2018-05-29 | 갈데르마 리써어치 앤드 디벨로프먼트 | Lactic acid bacteria-containing compositions and uses thereof for treating atopic dermatitis |
AU2018326705A1 (en) | 2017-08-30 | 2020-03-05 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
EP3716958B1 (en) * | 2017-11-28 | 2023-10-18 | Dermapharm AG | Composition for the treatment of dysbiosis of the intestinal microbiota |
DE102018000033A1 (en) * | 2018-01-03 | 2019-07-25 | Torsten Schott | Process for accelerated general and skin regeneration and wound healing |
GB202115797D0 (en) * | 2021-11-03 | 2021-12-15 | Iiaa Ltd | Compositions comprising probiotic and postbiotic strains of bacteria |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US539773A (en) * | 1895-05-21 | Carburetor | ||
US3920834A (en) * | 1970-07-10 | 1975-11-18 | Hoffmann La Roche | Light-screening compositions and method |
DE3024318A1 (en) * | 1980-06-27 | 1982-01-28 | Chemisches Laboratorium Dr. Karl Richter GmbH, 1000 Berlin | COSMETIC AGENTS |
US4646362A (en) * | 1985-01-10 | 1987-03-03 | Kimberly-Clark Corporation | Disposable underpants, such as child's training pants and the like |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US5223491A (en) * | 1989-11-09 | 1993-06-29 | Donzis Byron A | Method for revitalizing skin by applying topically water insoluble glucan |
CH680972A5 (en) * | 1990-09-28 | 1992-12-31 | Nestle Sa | |
DE69219768T2 (en) * | 1992-07-06 | 1997-08-28 | Societe Des Produits Nestle S.A., Vevey | Milk bacteria |
US5501857A (en) * | 1992-07-24 | 1996-03-26 | Midwestern Bio-Ag Products & Services, Inc. | Oral nutritional and dietary composition |
FR2698268B1 (en) | 1992-11-24 | 1995-01-20 | Oreal | Photoprotective composition administered orally. |
JP3347381B2 (en) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | Pet food |
FR2718752B1 (en) | 1994-04-15 | 1996-07-12 | World Trust Investment Sa | Preparations based on fermented whey and their uses. |
FR2725896B1 (en) | 1994-10-19 | 1996-11-29 | Sederma Sa | NEW COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS |
IT1274654B (en) | 1995-02-28 | 1997-07-18 | Newpharma Srl | ASSOCIATIONS OF LACTIC FERMENTS AND SACCHAROMETIC LYSATES THEIR THERAPEUTIC USE AND COMPOSITIONS CONTAINING THEM |
FR2749758B1 (en) * | 1996-06-12 | 1998-08-07 | Oenobiol Sa Lab | COMPOSITION WITH TANNING AND PHOTOPROCTOR ACTIVITY AND ITS AESTHETIC APPLICATIONS |
US6030650A (en) * | 1996-11-22 | 2000-02-29 | Princeton Nutrition, L.L.C. | Complete nutritional milk compositions and products |
PT931543E (en) * | 1997-12-19 | 2002-09-30 | Merck Patent Gmbh | TABLETS OF SEVERAL LAYERS CONTAINING PROBIOTIC MICROORGANISMS AS FOR EXAMPLE LACTOBACILUS OR BIFIDOBACTERIAS |
ATE314858T1 (en) * | 1998-04-01 | 2006-02-15 | Ganeden Biotech Inc | EXPERIENCE IN REDUCING CHOLESTEROL WITH BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS |
DE19819475A1 (en) * | 1998-04-30 | 1999-11-04 | Basf Ag | Dry microorganism cultures and methods for their production |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
NL1010770C2 (en) | 1998-12-09 | 2000-06-13 | Nutricia Nv | Preparation containing oligosaccharides and probiotics. |
EP1020123A1 (en) * | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
SE523771C2 (en) * | 1999-05-21 | 2004-05-18 | Probi Ab | Sports drinks containing micronutrients in combination with live lactobacilli |
JP2001000142A (en) * | 1999-06-23 | 2001-01-09 | Artnature Co Ltd | Nutritive assistance food for hair restoration and hair growth |
UY26331A1 (en) * | 1999-09-09 | 2001-04-30 | Societes Des Produits Nestle S | IMPROVING THE CONDITION OF ANOUSY PETS |
EP1110555A1 (en) * | 1999-12-22 | 2001-06-27 | Societe Des Produits Nestle S.A. | Antiadhesive agent for the pathogen flora of the skin |
US6617356B2 (en) * | 2000-01-03 | 2003-09-09 | Naturally Scientific Inc | Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements |
EP1276488B1 (en) * | 2000-03-24 | 2006-12-20 | Societe Des Produits Nestle S.A. | Use of lactic acid bacterium for the prevention of peritonitis |
EP1151673A3 (en) * | 2000-05-03 | 2002-01-02 | Societe Des Produits Nestle S.A. | Confectionery product having a filling |
WO2002028402A1 (en) * | 2000-10-06 | 2002-04-11 | Société des Produits Nestlé S.A. | Use of probiotic lactic acid bacteria for balancing the skin's immune system |
US6864231B2 (en) | 2001-01-09 | 2005-03-08 | Pharmachem Laboratories, Inc. | Glycoprotein matrix compositions and methods related thereto |
US20040052852A1 (en) * | 2001-09-25 | 2004-03-18 | Michael Farber | Carbohydrate-based delivery system for creatine and other bioactive ingredients |
PT1490077E (en) * | 2002-02-21 | 2008-02-28 | Oreal | A photoprotective orally administrable composition for skin |
EP1478242B1 (en) * | 2002-02-21 | 2014-04-30 | Societe Des Produits Nestle S.A. | Pet food composition for skin photoprotection |
DE60305159T2 (en) * | 2002-02-21 | 2007-03-15 | Société des Produits Nestlé S.A. | ORAL ADMINISTRATIVE COMPOSITION FOR THE PROTECTION OF THE SKIN FROM LIGHT |
-
2003
- 2003-02-18 DE DE60305159T patent/DE60305159T2/en not_active Expired - Lifetime
- 2003-02-18 CN CNB038042916A patent/CN1301708C/en not_active Expired - Fee Related
- 2003-02-18 MX MXPA04008177A patent/MXPA04008177A/en active IP Right Grant
- 2003-02-18 ES ES03742550T patent/ES2263990T3/en not_active Expired - Lifetime
- 2003-02-18 UA UA20040907624A patent/UA77066C2/en unknown
- 2003-02-18 BR BRPI0307875-2A patent/BR0307875B1/en not_active IP Right Cessation
- 2003-02-18 PT PT03742550T patent/PT1478329E/en unknown
- 2003-02-18 CA CA2477144A patent/CA2477144C/en not_active Expired - Lifetime
- 2003-02-18 WO PCT/EP2003/001685 patent/WO2003070203A1/en active IP Right Grant
- 2003-02-18 RU RU2004127986/15A patent/RU2309760C2/en not_active IP Right Cessation
- 2003-02-18 AU AU2003232184A patent/AU2003232184B2/en not_active Ceased
- 2003-02-18 US US10/505,305 patent/US20050069505A1/en not_active Abandoned
- 2003-02-18 JP JP2003569163A patent/JP2005526038A/en active Pending
- 2003-02-18 EP EP03742550A patent/EP1478329B1/en not_active Expired - Lifetime
- 2003-02-18 AT AT03742550T patent/ATE325604T1/en active
- 2003-02-18 PL PL03372146A patent/PL372146A1/en not_active Application Discontinuation
- 2003-02-18 KR KR10-2004-7013096A patent/KR20040096604A/en not_active Application Discontinuation
- 2003-02-18 DK DK03742550T patent/DK1478329T3/en active
- 2003-02-21 TW TW092103673A patent/TWI344845B/en not_active IP Right Cessation
- 2003-02-24 AR ARP030100588A patent/AR038594A1/en not_active Application Discontinuation
-
2004
- 2004-09-14 NO NO20043848A patent/NO20043848L/en not_active Application Discontinuation
- 2004-09-20 ZA ZA200407551A patent/ZA200407551B/en unknown
-
2005
- 2005-12-06 HK HK05111123A patent/HK1079104A1/en not_active IP Right Cessation
-
2007
- 2007-07-02 US US11/772,704 patent/US10688139B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2003232184A1 (en) | 2003-09-09 |
DE60305159T2 (en) | 2007-03-15 |
ES2263990T3 (en) | 2006-12-16 |
PL372146A1 (en) | 2005-07-11 |
CN1301708C (en) | 2007-02-28 |
JP2005526038A (en) | 2005-09-02 |
HK1079104A1 (en) | 2006-03-31 |
US20070280999A1 (en) | 2007-12-06 |
TWI344845B (en) | 2011-07-11 |
MXPA04008177A (en) | 2005-06-08 |
ZA200407551B (en) | 2005-10-12 |
DE60305159D1 (en) | 2006-06-14 |
AR038594A1 (en) | 2005-01-19 |
UA77066C2 (en) | 2006-10-16 |
RU2309760C2 (en) | 2007-11-10 |
DK1478329T3 (en) | 2006-08-28 |
BR0307875B1 (en) | 2014-12-23 |
CN1635865A (en) | 2005-07-06 |
CA2477144C (en) | 2011-06-14 |
KR20040096604A (en) | 2004-11-16 |
RU2004127986A (en) | 2005-05-10 |
CA2477144A1 (en) | 2003-08-28 |
AU2003232184B2 (en) | 2008-11-13 |
TW200307555A (en) | 2003-12-16 |
WO2003070203A1 (en) | 2003-08-28 |
PT1478329E (en) | 2006-09-29 |
US10688139B2 (en) | 2020-06-23 |
US20050069505A1 (en) | 2005-03-31 |
ATE325604T1 (en) | 2006-06-15 |
BR0307875A (en) | 2004-12-28 |
EP1478329A1 (en) | 2004-11-24 |
NO20043848L (en) | 2004-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1478329B1 (en) | Orally administrable composition for the photoprotection of the skin | |
EP1490077B1 (en) | A photoprotective orally administrable composition for skin | |
US8377679B2 (en) | Use of probiotic lactic acid bacteria for balancing the skin's immune system | |
AU2002220587A1 (en) | Use of probiotic lactic acid bacteria for balancing the skin's immune system | |
AU2003210310B2 (en) | A photoprotective orally administrable composition for skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040921 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
17Q | First examination report despatched |
Effective date: 20050331 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060510 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/06 20060101ALI20060320BHEP Ipc: A61K 35/74 20060101ALI20060320BHEP Ipc: A61K 31/07 20060101ALI20060320BHEP Ipc: A61K 8/99 20060101AFI20060320BHEP |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 60305159 Country of ref document: DE Date of ref document: 20060614 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Effective date: 20060731 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20060402762 Country of ref document: GR |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2263990 Country of ref document: ES Kind code of ref document: T3 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20070213 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060810 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061111 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60305159 Country of ref document: DE Representative=s name: ANDRAE WESTENDORP PATENTANWAELTE PARTNERSCHAFT, DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 14 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 15 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20180208 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20180129 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20180314 Year of fee payment: 16 Ref country code: GR Payment date: 20180116 Year of fee payment: 16 Ref country code: IE Payment date: 20180212 Year of fee payment: 16 Ref country code: TR Payment date: 20180209 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60305159 Country of ref document: DE Representative=s name: MITSCHERLICH, PATENT- UND RECHTSANWAELTE PARTM, DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20181217 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20190212 Year of fee payment: 17 Ref country code: AT Payment date: 20190125 Year of fee payment: 17 Ref country code: SE Payment date: 20190212 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190218 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190218 Ref country code: SK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190218 |
|
REG | Reference to a national code |
Ref country code: SK Ref legal event code: MM4A Ref document number: E 972 Country of ref document: SK Effective date: 20190218 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190904 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190218 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20200229 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 325604 Country of ref document: AT Kind code of ref document: T Effective date: 20200218 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20200229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200229 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210112 Year of fee payment: 19 Ref country code: PT Payment date: 20210217 Year of fee payment: 19 Ref country code: NL Payment date: 20210212 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210202 Year of fee payment: 19 Ref country code: ES Payment date: 20210310 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20211230 Year of fee payment: 20 Ref country code: FR Payment date: 20211216 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20211216 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60305159 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20220301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220818 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220301 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220901 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20230217 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230302 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220218 Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20230217 |